Welcome to Medicom’s ESMO Focus on Genitourinary Tumours, where we bring the Congress to the Physician by bringing you the latest and most impactful developments in medical research. I’m your host, Dr Rachel Giles, and today we’re continuing our exploration of the latest GU oncology research reported at the European Society of Medical Oncology or -ESMO2024- that’s reshaping treatment approaches across different cancers. In this episode, we’ll cover 6 groundbreaking studies that focus on renal cell carcinoma, prostate cancer, and bladder cancer, highlighting promising therapies and new insights. If you’re a healthcare professional, this episode is full of essential updates to keep you informed.
Segment 1: Tivozanib Monotherapy – A Post-ICI Option in RCC
Segment 2: CONTACT-02 Trial – Advancing Prostate Cancer Therapy
Segment 3: Radium-223 and Enzalutamide in Bone Metastases
Segment 4: Darolutamide and ADT for Metastatic Prostate Cancer in ARANOTE
Segment 5: Fecal Transplants in Metastatic RCC Treatment
Segment 6: Neoadjuvant Durvalumab in Muscle-Invasive Bladder Cancer
Today’s episode covers some of the most impactful studies in GU oncology, from advanced renal cell carcinoma to castration-resistant prostate cancer and muscle-invasive bladder cancer. These trials not only highlight new therapeutic options but also provide crucial insights into the evolving understanding of how we can better tailor treatments to improve patient outcomes. Thank you for joining us for this deep dive into cutting-edge cancer research. I hope these findings will inspire you to re-evaluate treatment strategies in your practice and explore how these innovations could benefit your patients. Until next time, stay curious and keep advancing the field of medicine!
Posted on
Previous Article
« ESC 2024 Podcast Next Article
Gut microbiota modulates inflammation and cortical damage »
« ESC 2024 Podcast Next Article
Gut microbiota modulates inflammation and cortical damage »
Table of Contents: ESMO 2024
Featured articles
Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial
Gastrointestinal Cancer
Neoadjuvant chemoradiation does not improve surgical outcomes or survival in pancreatic cancer
Adding lenvatinib plus pembrolizumab to TACE improves PFS in intermediate-stage HCC
Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time
Pre-operative chemoradiation does not improve survival in resectable gastric cancer
Final results of the IKF-AIO-Moonlight trial
Gastrointestinal: Colorectal Cancer
Retifanlimab boosts survival in patients with anal cancer
NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer
Organ-preserving regimens in rectal cancer
No benefit of high-dose vitamin D3 supplementation in mCRC
Breast Cancer
Trastuzumab deruxtecan also effective in patients with brain metastases
High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC
Local HER2 IHC0 is often HER2-low or -ultralow
First-line capivasertib improves PFS but not OS in metastatic TNBC
Breastfeeding does not increase the risk of breast cancer recurrence
Lung Cancer
Adjuvant durvalumab does not improve survival in completely resected NSCLC
NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC
Relatlimab addition benefits only a subgroup of metastatic NSCLC
Melanoma
Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma
New neoadjuvant combinations in stage III melanoma
Genitourinary Cancer
Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC
Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection
Faecal transplants show promise in enhancing metastatic RCC treatment
Genitourinary: Prostate Cancer
Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases
177Lu-PSMA effective both in mCRPC and mHSPC
Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer
Final OS for CONTACT-02 trial in mCRPC
Gynaecological Cancer
Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer
Doublet maintenance therapy does not outperform monotherapy in ovarian cancer
Benefit of pembrolizumab in dMMR, newly diagnosed, high-risk endometrial cancer
No OS benefit of niraparib maintenance in high-risk ovarian cancer
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com